Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 12, 2017Human Vaccines & ImmunotherapeuticsOpen Access

Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZhigang ZhangChang'an UniversityJZJun ZhangKunming University of Science and TechnologyNXNingshao XiaXiamen University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhang et al. (2017) studied this question.

synapsesocial.com/papers/6a705dcb660549caf2c4f12ehttps://doi.org/10.1080/21645515.2017.1346755
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlation between Mouse Potency and In Vitro Relative Potency for Human Papillomavirus Type 16 Virus-Like Particles and Gardasil® Vaccine Samples2005 · 90 citations
  2. 2An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany2016 · 44 citations
  3. 3The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model2016 · 43 citations
  4. 4Adolescent Male Human Papillomavirus Vaccination2016 · 10 citations
  5. 5Evolution of type-specific immunoassays to evaluate the functional immune response to GARDASIL®, a vaccine for Human Papillomavirus types 16, 18, 6, and 112008 · 51 citations